Skip to main content
MyDeficiencies

Somatrogon

Long-acting recombinant human growth hormone analog, hGH fused with carboxy-terminal peptide (CTP) of hCG beta-subunit, growth hormone receptor agonist

Also sold as Ngenla.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Somatrogon has no classical pharmacokinetic depletion mechanism. It is a genetically engineered fusion protein in which the human growth hormone (hGH) sequence is joined to copies of the carboxy-terminal peptide (CTP) of the beta subunit of human chorionic gonadotropin, attached at the N- and C-termini (molecular weight approximately 30,465 Da, aglycosylated). The label states that "metabolism of somatrogon-ghla is believed to be classical protein catabolism, with subsequent recovery of the amino acids," meaning it is not a cytochrome P450 substrate. There is no oral absorption route (subcutaneous injection only), so chelation, gastric-pH, bile-acid-sequestration, and transporter-competition mechanisms cannot apply, and the drug has not been studied in renal or hepatic impairment. This pharmacokinetic profile is broadly similar to the other long-acting growth hormone products already reviewed in this project (lonapegsomatropin, somapacitan-beco), but the underlying chemistry is meaningfully different and is disclosed as such throughout this dossier: somatrogon is not a prodrug that releases free, unmodified somatropin the way lonapegsomatropin does. The CTP-fused molecule itself circulates and binds the GH receptor directly, engaging the same downstream JAK2/STAT5b signal transduction pathway as native growth hormone, but with different receptor-binding kinetics that are what produce its long effective half-life (37.7 hours, the longest of the three long-acting GH products reviewed in this project) rather than a cleavable-linker delayed-release mechanism. Because the circulating molecule is structurally distinct from native somatropin, class-level extrapolation from the daily-somatropin literature is a real but somewhat weaker mechanistic bridge for somatrogon than it was for lonapegsomatropin, and this is flagged explicitly in every affected entry below.

Long-acting recombinant human growth hormone analog, hGH fused with carboxy-terminal peptide (CTP) of hCG beta-subunit, growth hormone receptor agonist · ATC H01AC08 · also sold as Ngenla · reviewed 2026-09-29. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Somatrogon in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Phosphate, alkaline phosphatase and PTH, excess-direction

Orange — Moderate

See study details

Somatrogon measurably raises serum phosphorus, alkaline phosphatase, and parathyroid hormone per its own FDA label; this is an excess-direction bone-turnover effect, not a phosphate deficiency, though the label does not quantify the magnitude the way lonapegsomatropin's label does.

Full detail, limits and 1 references

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. orange

Limits on what this shows

  • Key negative/null findings: No source located found somatrogon lowering phosphate, ALP, or PTH; the effect is consistently reported in one direction across the label.
  • At-risk subgroups: Patients with pre-existing hyperphosphatemia or chronic kidney disease, where renal phosphate clearance is already impaired (extrapolated from the somatropin-class mechanism; not separately studied for somatrogon, which has not been studied in renal impairment at all per Section 8).

Regulatory status

NGENLA US PI, Section 5.14 (Laboratory Tests): "Serum levels of phosphorus, alkaline phosphatase, and parathyroid hormone may increase with NGENLA therapy." Medscape's clinician-facing monitoring summary echoes this as a labeled monitoring point.

Population evidence

FDA label Section 5.14, drawn from the drug's own 12-month, 224-patient (109 somatrogon, 115 daily somatropin) pivotal registration trial (NCT02968004, published as Deal et al. 2022, J Clin Endocrinol Metab). No separate shift percentage (baseline-normal-to-elevated) is broken out for phosphorus, ALP, or PTH in the label text located during this review, unlike lonapegsomatropin's label, which does provide such a shift percentage for the same lab pair.

Mechanism

Named, extrapolated from the shared GH-receptor pathway: GH/IGF-1 increases osteoblastic bone turnover and renal tubular phosphate reabsorption, raising serum phosphate, alkaline phosphatase, and (via reduced calcium filtration or direct stimulation) PTH as growth accelerates.

Counter-evidence held on record

No source found suggests somatrogon lowers phosphate, ALP, or PTH. The absence of a quantified shift percentage in the label (compared with lonapegsomatropin's label) is disclosed explicitly rather than implied to be a stronger or weaker effect than it is. Excess-direction finding. No phosphate supplementation is ever indicated here; monitor for hyperphosphatemia specifically in patients with renal impairment, which has not been studied for this drug. This mirrors the identical labeled direction for daily somatropin and lonapegsomatropin, since somatrogon activates the same GH-receptor pathway.

  • Deal CL, Steelman J, Vlachopapadopoulou E, et al. Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study. — Pivotal registration RCT (NCT02968004), n=224 (109 somatrogon, 115 daily somatropin), prepubertal children, 12 months. Used for IGF-1 SDS, glucose/HbA1c/insulin, anemia adverse-event rate, and bone-age data. PubMed's individual abstract page was inaccessible via direct fetch (bot-verification) on the first attempt during this review; the Oxford Academic full-text page was used successfully instead.PubMed direct abstract page (pubmed.ncbi.nlm.nih.gov/35405011) returned a bot-verification/reCAPTCHA page on the first fetch attempt in this review; the Oxford Academic article page (academic.oup.com/jcem/article/107/7/e2717/6566444) was used successfully as the source of record instead.

Fluid retention, dose-dependent

Orange — Moderate

See study details

Somatrogon produces dose-dependent fluid retention (edema, nerve compression syndromes including carpal tunnel); this is an excess/retention effect, not a sodium or fluid deficiency.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. orange

Limits on what this shows

  • Key negative/null findings: Label states the effect is usually transient and dose dependent; no incidence percentage specific to fluid retention is broken out in the sections reviewed.
  • At-risk subgroups: Adults and patients with pre-existing hypertension, heart failure, or other edema-prone states (extrapolated from the somatropin-class pattern; somatrogon's approved indication is pediatric GHD ages 3 and older, so adult-specific incidence has not been separately established for this drug).

Regulatory status

NGENLA US PI, Section 5.6: "Fluid retention during NGENLA therapy may occur. Clinical manifestations of fluid retention (e.g. edema and nerve compression syndromes including carpal tunnel syndrome/paresthesia) are usually transient and dose dependent."

Population evidence

FDA label, Tier A, drug-specific labeling based on the NGENLA clinical development program. The label does not separately quantify incidence for this specific manifestation the way it does for the overall adverse-reaction table (injection site reactions, nasopharyngitis, headache, pyrexia, anemia, and others, all listed at ≥5%).

Mechanism

Extrapolated from the somatropin class: GH stimulates the renin-angiotensin-aldosterone axis and renal epithelial sodium channel (ENaC) activity, promoting sodium and secondary water reabsorption. The NGENLA label does not name this specific mechanism for somatrogon; it is carried over from the shared GH-receptor pathway.

Counter-evidence held on record

No source located suggests somatrogon causes fluid or sodium loss. This is a retention/excess risk, not a depletion. Sodium supplementation is not indicated and could worsen fluid overload. Symptomatic retention should go to the prescriber for dose review, not to independent dietary changes.

Glucose metabolism, decreased insulin sensitivity

Orange — Moderate

See study details

Somatrogon's labeled reduction in insulin sensitivity produced a modest rise in fasting glucose, HbA1c, and insulin in its own pivotal trial, remaining within the normal range through 12 months and stable through 3 years of extension follow-up; this is an excess-direction glucose effect bounded by the trial's own normal-range data, not a nutrient deficiency.

Full detail, limits and 2 references

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. orange

Limits on what this shows

  • Key negative/null findings: Both the 12-month pivotal trial and the 3-year extension explicitly report the rise stayed within the normal reference range at the population level; this is itself a meaningful negative finding against a clinically significant population-wide glucose effect. Two Crossref-indexed Reactions Weekly items ("Somatrogon: Hyperglycaemia," 2018; "Somatrogon: Increased fasting sugar," 2019) were located and opened, but their cited underlying references resolved to studies unrelated to somatrogon (generic rhGH in Chinese children with idiopathic short stature, and an unrelated anaesthesia case report), so neither could be verified as a genuine somatrogon-specific case and neither is relied on here.
  • At-risk subgroups: Patients with obesity, Turner syndrome, or a family history of diabetes mellitus, per the label's own risk-factor language; not separately quantified by subgroup in the trial data located.

Regulatory status

NGENLA US PI, Section 5.4: "Treatment with growth hormone may decrease insulin sensitivity, particularly at higher doses. New onset type 2 diabetes mellitus has been reported in patients receiving growth hormone," with specific caution for patients with obesity, Turner syndrome, or a family history of diabetes. Section 7: "Patients with diabetes mellitus may require adjustment of their doses of insulin and/or other antihyperglycemic agents." Medscape's clinician monitoring summary independently confirms: "Monitor glucose levels periodically in all patients, especially those with risk factors for diabetes mellitus" and "patients with undiagnosed prediabetes and diabetes mellitus may experience worsened glycemic control."

Population evidence

Deal et al. (2022), the Phase 3 pivotal trial (NCT02968004), J Clin Endocrinol Metab, PMID 35405011, DOI 10.1210/clinem/dgac220, n=224 (109 somatrogon, 115 daily somatropin), 12 months: "Glucose, HbA1c, and insulin levels rose modestly during the 12-month period in both...groups; values remained within the normal range." Stawerska et al. (2026), the 3-year open-label extension, Horm Res Paediatr, PMID 42224388, DOI 10.1159/000552183, n=212 (OLE Year 1) and n=177 (OLE Year 2): "Mean glycated hemoglobin levels at the end of OLE Y1 and Y2 were largely unchanged" and remained "within the normal range (<5.7%)."

Mechanism

Named: GH/IGF-1 antagonizes insulin action and suppresses its anti-lipolytic effect, producing insulin resistance; this is the shared GH-receptor-pathway mechanism, not somatrogon-specific chemistry.

Counter-evidence held on record

The trial's own population-level data is reassuring: glucose, HbA1c, and insulin rose but stayed within normal limits at both 12 months and 3 years. This is disclosed as a bounding counter-evidence rather than omitted, and the two individual case-report titles found via Crossref that might have suggested a more severe picture could not be verified as somatrogon-specific on inspection. Excess-direction glucose effect. Not a basis for any dietary sugar restriction claim beyond ordinary glucose monitoring; insulin or antihyperglycemic dose adjustment is a prescriber decision, especially in patients with obesity or a diabetes risk factor.

  • Deal CL, Steelman J, Vlachopapadopoulou E, et al. Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study. — Pivotal registration RCT (NCT02968004), n=224 (109 somatrogon, 115 daily somatropin), prepubertal children, 12 months. Used for IGF-1 SDS, glucose/HbA1c/insulin, anemia adverse-event rate, and bone-age data. PubMed's individual abstract page was inaccessible via direct fetch (bot-verification) on the first attempt during this review; the Oxford Academic full-text page was used successfully instead.PubMed direct abstract page (pubmed.ncbi.nlm.nih.gov/35405011) returned a bot-verification/reCAPTCHA page on the first fetch attempt in this review; the Oxford Academic article page (academic.oup.com/jcem/article/107/7/e2717/6566444) was used successfully as the source of record instead.
  • Stawerska R, et al. Extension of the Phase 3 Trial of Somatrogon in Children with Growth Hormone Deficiency: 3 Years of Safety and Efficacy. — Open-label 3-year extension of the pivotal trial, n=212 (OLE Year 1), n=177 (OLE Year 2). Used for long-term IGF-1 SDS, HbA1c stability, and adverse-event rate data.

IGF-1, supraphysiologic peak with a defined subgroup crossing the dose-reduction threshold

Orange — Moderate

See study details

Somatrogon's once-weekly dosing produces a real, quantified IGF-1 pharmacodynamic peak (approximately 48 hours post-dose), and in real-world use a defined subgroup of patients (about 13% in one cohort) exceeds the protocol-defined IGF-1 SDS threshold of +2.0 early in treatment, triggering a mandated dose reduction, a bounded, drug-specific finding rather than a population-wide effect.

Full detail, limits and 3 references

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. orange

Limits on what this shows

  • Key negative/null findings: Bone-age advancement, a marker tied to over-exposure risk, was "similar between treatment groups" in the pivotal trial (somatrogon 1.07 vs. somatropin 1.12, ratio of bone-age change to chronological-age change), suggesting the IGF-1 fluctuation does not translate into excess skeletal maturation relative to daily dosing at the population level.
  • At-risk subgroups: Treatment-naive patients early in therapy, per the Tamaro et al. real-world cohort (13% exceeding +2 SDS), versus patients switched from another GH product, who showed no significant IGF-1 change in the same study.

Regulatory status

NGENLA US PI, Section 12.2 (Pharmacodynamics): "IGF-1 levels peak approximately 2 days (48 hours) post-dose, with the average weekly IGF-1 occurring approximately 4 days post-dose." Not framed as a warning in the label, but the underlying trial protocol built a mandatory dose-reduction rule around it.

Population evidence

CADTH Clinical Review of somatrogon (NCBI Bookshelf, NBK605092), summarizing the pivotal trial protocol: dose reduction was triggered by "2 repeated day-4 levels of IGF-I greater than 2.0 SDS," with the "most recent dose...reduced by 15%," targeting normalization to "IGF-I SDS between -0.5 and 1.5, inclusive." Deal et al. (2022), PMID 35405011: mean IGF-1 SDS at 12 months was 0.65 (range -3.64 to 3.22) for somatrogon versus -0.69 for daily somatropin, from baselines of -1.95 and -1.72 respectively; samples 48 to 72 hours post-dose represent the somatrogon peak. Tamaro et al. (2026), a real-world cohort, Frontiers in Endocrinology, DOI 10.3389/fendo.2026.1685851, n=40: treatment-naive patients' IGF-1 SDS rose to +2.36 at 6 months, and "IGF-1 exceeded +2 SDS in 13% of patients during the early phase," requiring dose reductions per protocol. Stawerska et al. (2026), 3-year extension, PMID 42224388: mean IGF-1 SDS remained elevated at 1.21 (OLE Year 1) and 1.25 (OLE Year 2), a change from baseline of roughly 2.96-2.97 SDS, sustained over multiple years.

Mechanism

Named and directly measured: once-weekly subcutaneous dosing with a 37.7-hour effective half-life necessarily produces a rise-then-decay IGF-1 concentration profile across a 7-day interval, with dose-titration protocols built specifically around the day-4 peak-adjacent sampling window.

Counter-evidence held on record

The same bone-age data that would flag a harmful over-exposure effect showed no meaningful difference from daily dosing, and the trial protocol's own automatic dose-reduction rule is designed to correct the excursion once identified. This is a pharmacodynamic characteristic of the weekly dosing format, not a nutrient effect. It is graded orange rather than yellow because a real, quantified subgroup (about 13% in the cited real-world cohort) crosses a protocol-defined threshold requiring intervention, unlike a purely theoretical or class-level signal. IGF-1 remains the standard monitoring marker for dose titration regardless.

  • Deal CL, Steelman J, Vlachopapadopoulou E, et al. Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study. — Pivotal registration RCT (NCT02968004), n=224 (109 somatrogon, 115 daily somatropin), prepubertal children, 12 months. Used for IGF-1 SDS, glucose/HbA1c/insulin, anemia adverse-event rate, and bone-age data. PubMed's individual abstract page was inaccessible via direct fetch (bot-verification) on the first attempt during this review; the Oxford Academic full-text page was used successfully instead.PubMed direct abstract page (pubmed.ncbi.nlm.nih.gov/35405011) returned a bot-verification/reCAPTCHA page on the first fetch attempt in this review; the Oxford Academic article page (academic.oup.com/jcem/article/107/7/e2717/6566444) was used successfully as the source of record instead.
  • Stawerska R, et al. Extension of the Phase 3 Trial of Somatrogon in Children with Growth Hormone Deficiency: 3 Years of Safety and Efficacy. — Open-label 3-year extension of the pivotal trial, n=212 (OLE Year 1), n=177 (OLE Year 2). Used for long-term IGF-1 SDS, HbA1c stability, and adverse-event rate data.
  • Tamaro G, Rodaro C, Fachin A, Fabretto A, Tornese G. Two-year real-world experience with somatrogon in children and adolescents with growth hormone deficiency. — Real-world cohort, n=40, March 2023-January 2025. Used for the IGF-1 threshold-excursion subgroup finding (13% exceeding +2 SDS in the early phase) and adverse-event data.

Vitamin D, class-level, no depletion found in the largest somatropin studies

Yellow — Low

See study details

No somatrogon-specific vitamin D study exists; chronic treatment with daily somatropin does not appear to deplete storage vitamin D (25-hydroxyvitamin D) in the two largest controlled studies, and GH/IGF-1 signaling directly stimulates conversion to the active hormone rather than depleting the storage form, carried into this dossier because somatrogon's own label documents a real PTH-axis effect (see Phosphate entry).

Full detail, limits and 4 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: The two largest, most recent studies (combined n=208 treated children) found no change in 25(OH)D with daily rhGH treatment; no study located found any GH product lowering 25(OH)D.
  • At-risk subgroups: GHD children have a high baseline prevalence of vitamin D insufficiency independent of treatment, reflecting the underlying condition rather than any GH product's pharmacology, per the confounding-by-indication rule.

Regulatory status

Not addressed in the NGENLA label beyond the PTH-increase language already cited in the Phosphate entry.

Population evidence

No study of somatrogon and vitamin D was found. PubMed title/abstract search for "somatrogon"[tiab] AND ("vitamin D"[tiab] OR "calcium"[tiab]) returned zero results, confirmed directly. Class-level: Wei, Tanaka, Kubo, Ono, Kanzaki, Seino (1997), Eur J Endocrinol, PMID 9037126, n=12 GHD children, 6 months of daily GH: 1,25-dihydroxyvitamin D increased (P<0.05); 25-hydroxyvitamin D (the standard status marker) unchanged. Durá-Travé et al. (2020), J Endocrinol Invest, PMID 32215862, n=98 GHD children vs. 247 controls, 24 months: GH therapy "didn't modify vitamin D levels." Durá-Travé & Gallinas-Victoriano (2022), Children (Basel), PMID 35626902, n=110 GHD children vs. 377 controls, 48 months: calcidiol unchanged (P=0.501) while PTH rose steadily (P<0.001) independent of vitamin D status. Hamza, Hamed, Sallam (2018), J Investig Med, DOI 10.1136/jim-2017-000618, n=50 GHD children vs. 50 controls: 25(OH)D rose after 1 year (P<0.001), a reverse-direction finding in tension with the two larger null studies. All four sources verified in this project's companion B002 and B005 dossiers; not independently re-fetched in this specific review given the tooling constraints described in Sources, disclosed explicitly.

Mechanism

Named: GH/IGF-1 stimulates renal 1-alpha-hydroxylase, increasing conversion of 25(OH)D to active 1,25(OH)2D, a conversion/activation effect, not a depletion of vitamin D stores. This mechanism would apply to any GH product effectively raising IGF-1 via the shared GH-receptor pathway, including somatrogon, though again the bridge runs through receptor activation rather than an identical circulating hormone.

Counter-evidence held on record

The two largest controlled cohorts are themselves the counter-evidence to any depletion claim, for daily-dosed somatropin; none of this is drug-specific to somatrogon. Reverse-direction or null class-level finding, not a depletion signal, and not a basis for withholding vitamin D monitoring in GHD children generally given the real, indication-linked baseline deficiency prevalence in this population.

  • Wei S, Tanaka H, Kubo T, Ono T, Kanzaki S, Seino Y. Growth hormone increases serum 1,25-dihydroxyvitamin D levels and decreases 24,25-dihydroxyvitamin D levels in children with growth hormone deficiency. — n=12 GHD children, 6 months daily GH. Verified in this project's companion B002/B005 dossiers; not independently re-fetched in this review. Used class-level for the Vitamin D entry.Not independently re-fetched in this review.
  • Durá-Travé T, Gallinas-Victoriano F, Moreno-González P, et al. Vitamin D status and response to growth hormone treatment in prepubertal children with growth hormone deficiency. — n=98 GHD children vs. 247 controls, 24 months daily GH; no change in vitamin D levels. Verified in this project's companion B002/B005 dossiers; not independently re-fetched in this review. Used class-level for the Vitamin D entry.Not independently re-fetched in this review.
  • Durá-Travé T, Gallinas-Victoriano F. Vitamin D and Parathyroid Hormone during Growth Hormone Treatment. — n=110 GHD children vs. 377 controls, 48 months. Calcidiol unchanged (P=0.501); PTH rose independent of vitamin D status. Verified in this project's companion B002/B005 dossiers; not independently re-fetched in this review. Used class-level for the Vitamin D entry and the Overlap map.Not independently re-fetched in this review.
  • Hamza RT, Hamed AI, Sallam MT. Vitamin D Status in Prepubertal Children with Isolated Idiopathic Growth Hormone Deficiency: Effect of Growth Hormone Therapy. — n=50 GHD children vs. 50 controls; 25(OH)D rose after 1 year of daily GH therapy. Verified in this project's companion B002/B005 dossiers; not independently re-fetched in this review. Used class-level as a reverse-direction finding, in tension with the larger null studies above.Not independently re-fetched in this review.

No entry is ungraded in this dossier

Not graded — disclosed evidence gap

See study details

Every one of the seven required physiological categories, and the one classical nutrient carried into this review, qualified for at least a yellow grade through class-level (Tier C) extrapolation from the shared GH-receptor/JAK2-STAT5b signaling pathway, rather than remaining an evidence gap.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. empty section

Limits on what this shows

  • Why no grade: Not applicable: this section is empty because somatrogon-specific evidence for mitochondrial burden, oxidative stress, copper, gut microbiome risk, and ATP production is genuinely absent (confirmed by direct, individually logged, zero-result PubMed title/abstract searches for each combination, see Sources), and oxygen delivery/utilization has only one non-differential drug-specific data point, but every one of the seven has real Tier B/C class-level supporting literature via the shared GH-receptor pathway somatrogon activates, which is sufficient under this protocol's rules to grade yellow rather than ungraded, even though the mechanistic bridge is disclosed as weaker than for lonapegsomatropin given somatrogon's distinct fused-molecule chemistry.

What would reopen this section

A future finding that any yellow-graded class-level source turns out not to reflect the actual pharmacology of GH-receptor activation by the somatrogon fusion protein specifically, or a future search (once the tooling constraints disclosed in Sources are resolved) that could not locate even the class-level evidence currently cited, which would require re-evaluating that specific entry.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden, class-level evidence only

Yellow — Low

See study details

No somatrogon-specific mitochondrial study exists; the one human study of daily somatropin found no deficit in skeletal-muscle mitochondrial oxidative capacity in treated growth-hormone-deficient adults, evidence that applies to somatrogon only through the shared GH-receptor pathway, not an identical circulating molecule.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: Sinha et al. is itself the key null finding for the shared GH-receptor pathway, in treated humans, not an animal model.
  • At-risk subgroups: None identified.

Regulatory status

Not addressed in the NGENLA label.

Population evidence

No study of somatrogon and mitochondrial function was found. PubMed title/abstract search for "somatrogon"[tiab] AND "mitochondri"[tiab] returned zero results, confirmed directly during this review. Class-level: Sinha, Hollingsworth, Ball, Cheetham (2013/2014), Clin Endocrinol (Oxf), PMID 23711232. Cross-sectional study, n=65 (22 untreated GHD adults, 23 daily-somatropin-treated GHD adults, 20 healthy controls). Phosphorus-31 MRS measurement of skeletal-muscle phosphocreatine (PCr) recovery half-time, a direct marker of mitochondrial oxidative phosphorylation capacity. No significant difference across groups. This source was verified in this project's companion B002 (somatropin) and B005 (lonapegsomatropin) dossiers; it was not independently re-fetched in this specific review given the tooling constraints described in the Sources section, and that reliance is disclosed here explicitly.

Mechanism

Plausibility only, and a genuinely weaker bridge than for lonapegsomatropin: somatrogon activates the same GH-receptor/JAK2-STAT5b signaling pathway as native somatropin once bound, so any mitochondrial effect of GH-receptor activation itself would in principle apply, but the circulating molecule is a permanently fused hGH-CTP protein with altered receptor-binding kinetics, not a released, unmodified somatropin molecule the way lonapegsomatropin's active moiety is. This distinction is disclosed explicitly rather than treated as equivalent.

Counter-evidence held on record

No source located suggests any GH-class product harms mitochondrial function in humans. This entry documents that the human evidence for the shared receptor pathway is reassuring, not that somatrogon itself has been studied. See Overlap map for the shared source with ATP production.

  • Sinha A, Hollingsworth KG, Ball S, Cheetham T. Impaired quality of life in growth hormone-deficient adults is independent of the altered skeletal muscle oxidative metabolism found in conditions with peripheral fatigue. — Cross-sectional study, n=65 (22 untreated GHD, 23 daily-somatropin-treated GHD, 20 controls); 31P-MRS phosphocreatine recovery kinetics; no significant difference across groups. Verified in this project's companion B002 and B005 dossiers; not independently re-fetched in this specific review given the Europe PMC/Semantic Scholar/OpenAlex access constraints described below. Used class-level for the Mitochondrial burden and ATP production entries.Not independently re-fetched in this review; relied on prior verification from the companion B002/B005 dossiers, disclosed explicitly.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress, class-level, reverse-direction signal

Yellow — Low

See study details

No somatrogon-specific oxidative-stress study exists; a small preliminary study of daily somatropin found lower oxidative-stress markers and higher antioxidant capacity after 12 months of treatment, the opposite of a depletion pattern, evidence bridged to somatrogon only through the shared GH-receptor pathway.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: Nitric oxide showed no significant change in the same cohort; this is one small, unreplicated, non-peer-reviewed preprint of daily somatropin, never extended to somatrogon or any weekly GH formulation.
  • At-risk subgroups: None identified.

Regulatory status

Not addressed in the NGENLA label.

Population evidence

No study of somatrogon and oxidative stress was found. PubMed title/abstract search for "somatrogon"[tiab] AND "oxidative"[tiab] returned zero results, confirmed directly. Class-level: Kościuszko et al. (2024), Research Square preprint, not yet peer-reviewed, DOI 10.21203/rs.3.rs-4883080/v1, n=15 adult-onset GHD patients on daily somatropin (Omnitrope), followed to 12 months: total oxidative capacity fell (P=0.02 at 6 months, P=0.04 at 12 months), total antioxidant capacity rose at 12 months (P=0.02). Verified in this project's companion B002 and B005 dossiers; not independently re-fetched in this specific review, disclosed as such.

Mechanism

Not fully elucidated in the source; framed by its authors as part of a broader cardiovascular-risk-reduction effect of correcting GHD, using the shared GH-receptor pathway somatrogon also engages, though again via a structurally distinct fusion molecule rather than an identical circulating hormone.

Counter-evidence held on record

No study located shows any GH-class product worsening oxidative stress markers in humans. Reverse-direction (potentially protective) signal only, resting on one small, unreplicated preprint for a different molecule and dosing regimen. Not an established protective claim for somatrogon.

  • Kościuszko M et al. Cardiovascular Effects of Growth Hormone: Preliminary Study on Oxidative Stress in Adults with Growth Hormone Deficiency. — Prospective observational study, n=15 adult-onset GHD adults on daily somatropin (Omnitrope), 12-month follow-up. Verified in this project's companion B002 and B005 dossiers; not independently re-fetched in this review.Preprint, not yet peer-reviewed; graded as Tier B/C for the class, never Tier A or B for somatrogon specifically since the drug is not in this cohort. Not independently re-fetched in this review.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper, class-level, mechanistic and inconsistent

Yellow — Low

See study details

No somatrogon-specific copper study exists; direct human evidence on daily somatropin and copper status is old, small, and inconsistent, and the one chronic recombinant-GH study to measure a real copper-status marker found no significant change.

Full detail, limits and 3 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: Pankratova 2015 is the key null finding: ceruloplasmin unchanged after 12 months of daily recombinant GH in the pediatric GHD population, the most clinically relevant of the three class-level sources.
  • At-risk subgroups: Cannot be determined from the available evidence.

Regulatory status

Not addressed in the NGENLA label.

Population evidence

No study of somatrogon and copper was found. PubMed title/abstract search for "somatrogon"[tiab] AND "copper"[tiab] returned zero results, confirmed directly; a broader, non-restricted search also returned zero. Class-level, verified in this project's companion B002 and B005 dossiers: Brandão-Neto et al. (1988), Braz J Med Biol Res, PMID 3179576, n=7, acute IV hGH infusion, plasma copper fell at low dose and rose at high dose, a dose-dependent, non-monotonic acute effect; Aihara et al. (1985), J Pediatr Gastroenterol Nutr, PMID 4032177, pituitary-derived hGH era, direction/magnitude for copper specifically not confirmable beyond "copper, manganese, and selenium levels also shifted with hGH status changes"; Pankratova et al. (2015), PeerJ 3:e1055, DOI 10.7717/peerj.1055, n=11 treatment-naive GHD children, 12 months of daily recombinant GH, ceruloplasmin (the principal copper-status marker) showed no statistically significant change. None of these sources were independently re-fetched in this specific review; the tooling constraints encountered (see Sources) prevented fresh verification, and reliance on the companion dossiers' prior verification is disclosed explicitly.

Mechanism

Named but unresolved in direction: acute hGH dosing appears to acutely redistribute plasma copper in a dose-dependent, non-monotonic pattern; no confirmed mechanism or direction for chronic treatment, and this bridges to somatrogon only via the shared GH-receptor pathway, not an identical circulating molecule.

Counter-evidence held on record

The one study using a modern recombinant GH molecule and a real chronic copper-status marker found no significant change. No study of any kind exists for somatrogon specifically. Mechanistic and historical class-level evidence only; no confirmed chronic copper effect from any GH-class product. Not a basis for copper supplementation.

  • Brandão-Neto J, Kimachi T, Veríssimo JM, Shuhama T, Marchini JS, Antunes-Rodrigues J. Acute effects of human growth hormone on zinc, copper, calcium and magnesium metabolism in normal subjects. — Acute IV-infusion study, n=7 healthy adults, single 60-minute infusion of pituitary-derived hGH. Verified in this project's companion B002/B005 dossiers; not independently re-fetched in this review. Used class-level for the Copper entry.Single IV bolus dosing, not chronic subcutaneous dosing; opposite-direction results at two doses tested limit generalization. Not independently re-fetched in this review.
  • Aihara K, Nishi Y, Hatano S, et al. Zinc, copper, manganese, and selenium metabolism in patients with human growth hormone deficiency or acromegaly. — Pituitary-derived hGH era cohort. Verified in this project's companion B002/B005 dossiers; not independently re-fetched in this review. Used class-level for the Copper entry.Not independently re-fetched in this review.
  • Pankratova MS et al. Imbalance in the blood antioxidant system in growth hormone-deficient children before and after 1 year of recombinant growth hormone therapy. — n=11 treatment-naive GHD children, 12 months of daily recombinant GH; ceruloplasmin unchanged. Verified in this project's companion B002/B005 dossiers; not independently re-fetched in this review.Not independently re-fetched in this review.

Iron, class-level, growth-driven utilization signal

Yellow — Low

See study details

No somatrogon-specific iron study exists; in children treated with daily somatropin, GH/IGF-1-driven, erythropoietin-independent erythropoiesis measurably increased iron utilization during accelerated growth, shown as falling ferritin and rising transferrin, with the more specific functional-iron-deficiency marker unchanged.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: Soluble transferrin receptor, the marker most specific to functional iron deficiency, did not significantly change in the same cohort, indicating a store-level marker shift rather than confirmed tissue-level iron deficiency, for daily-dosed somatropin.
  • At-risk subgroups: Children undergoing GH-induced accelerated or catch-up growth, where iron demand from expanding red-cell mass is highest; somatrogon's own labeled anemia adverse-reaction rate (9.2%, see Oxygen delivery / utilization entry) is consistent with, though not proof of, ongoing red-cell-production activity in this population.

Regulatory status

Not addressed in the NGENLA label; iron status monitoring is not a labeled requirement.

Population evidence

No study of somatrogon and iron was found. PubMed title/abstract search for "somatrogon"[tiab] AND "iron"[tiab] returned zero results, confirmed directly. Class-level: Vihervuori, Cook, Siimes (1997), Acta Paediatr, DOI 10.1111/j.1651-2227.1997.tb08939.x, n=35 children with short stature given 6 months of daily GH treatment: serum ferritin decreased, serum transferrin increased, soluble transferrin receptor (the more specific functional marker) showed minimal change. Companion study, Vihervuori et al. (1996), Blood, n=40 short children on 12 months of rhGH: hemoglobin rose 0.42 g/dL overall, correlating with IGF-1/IGFBP-3 but not erythropoietin, indicating a GH/IGF-1-driven, erythropoietin-independent erythropoiesis mechanism that would apply to any GH product driving comparable growth acceleration, including somatrogon. Verified in this project's companion B002 and B005 dossiers; not independently re-fetched in this specific review, disclosed as such.

Mechanism

Named, class-level: GH/IGF-1 directly stimulates bone-marrow erythropoiesis independent of erythropoietin, increasing red-cell production and consuming iron stores faster than the ferritin pool passively replaces, during periods of GH-driven accelerated growth. This mechanism operates downstream of GH-receptor activation, which somatrogon shares with somatropin even though the two circulating molecules differ structurally.

Counter-evidence held on record

No study located found iron overload or a stable/unaffected iron profile with any GH product; direction (increased utilization) is consistent across the two Vihervuori studies, which describe the same erythropoiesis-stimulation mechanism in overlapping accelerated-growth cohorts (see Overlap map). This class-level signal supports monitoring iron status during periods of rapid GH-induced growth on any GH product, not empiric iron supplementation. No iron dose is recommended here; iron repletion without a measured deficit carries its own overload risk.

  • Vihervuori E, Cook JD, Siimes MA. Iron status of children with short stature during accelerated growth due to growth hormone treatment. — n=35 children with short stature, 6 months of daily GH treatment. Ferritin decreased, transferrin increased, soluble transferrin receptor minimally changed. Verified in this project's companion B002/B005 dossiers; not independently re-fetched in this review. Used class-level for the Iron entry.Not independently re-fetched in this review.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk, mechanism-only, class-level

Yellow — Low

See study details

No somatrogon-specific or somatropin-specific human microbiome study exists; genetic deletion of the growth hormone receptor alters mouse gut microbiota and bile-acid metabolism, suggesting the GH axis generally affects the microbiome, with no data on exogenous administration of any GH product, including somatrogon.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: No human data for any GH product; no study administering somatrogon, lonapegsomatropin, or daily somatropin and measuring microbiome composition was found despite a genuine multi-phrase, multi-channel search.
  • At-risk subgroups: Cannot be determined from available evidence.

Regulatory status

Not addressed in the NGENLA label; no microbiome monitoring is recommended.

Population evidence

No study of somatrogon and the gut microbiome was found. PubMed title/abstract search for "somatrogon"[tiab] AND "microbiome"[tiab] returned zero results, confirmed directly (a broader, non-tiab-restricted search initially returned five results via PubMed's automatic term-broadening, none of which actually concerned somatrogon or the microbiome, confirming the zero-result finding rather than contradicting it). Class-level: Yu, Wang, Zhang et al. (2023), Gut Microbes, DOI 10.1080/19490976.2023.2221098. Mouse model with hepatic growth hormone receptor (GHR) gene deletion, the opposite manipulation from GH administration, found altered gut microbial composition mediated by changed bile-acid metabolism. Verified in this project's companion B002 and B005 dossiers; a fresh fetch attempt in this review of the Europe PMC and Crossref-bibliographic channels did not return this specific source, disclosed as a tooling limitation rather than a retraction of the prior verification.

Mechanism

Named but indirect: hepatic GH signaling affects bile-acid synthesis and composition, which shapes the gut microbial community. Shown by removing GH signaling, not by adding exogenous GH of any formulation, and the receptor-signaling step itself (not the specific circulating molecule) is the presumed common link to somatrogon.

Counter-evidence held on record

None found in either direction in humans, for any GH product. Direction of effect for actual GH-receptor agonism (as opposed to receptor loss) cannot be inferred from a knockout model. Treat as biological plausibility only.

  • Yu Z, Wang Y, Zhang F, et al. Deletion of hepatic growth hormone receptor (GHR) alters the mouse gut microbiota by affecting bile acid metabolism. — Mouse hepatic GHR-knockout model (loss of GH signaling), not exogenous GH administration. Verified in this project's companion B002 and B005 dossiers; not independently re-fetched in this review.Not independently re-fetched in this review; relied on prior verification from the companion B002/B005 dossiers, disclosed explicitly.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery / utilization, drug-specific null plus class-level reverse-direction signal

Yellow — Low

See study details

Somatrogon's own FDA label and pivotal trial report anemia as an adverse reaction at a rate statistically indistinguishable from active-comparator daily somatropin (9.2% vs. 8.7%), a real but non-differential drug-specific data point; growth hormone deficiency itself is separately an established, mild, treatable cause of anemia via reduced GH/IGF-1-driven erythropoiesis, a class-level mechanism that would apply to any effective GH replacement, including somatrogon.

Full detail, limits and 2 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: The near-identical anemia rate between somatrogon and daily somatropin is itself the most direct drug-specific finding located: it argues against any differential oxygen-delivery risk specific to somatrogon relative to the established comparator, though this is an active-comparator trial with no untreated arm, so it cannot rule out an effect shared by both GH products relative to no treatment.
  • At-risk subgroups: Children/adults with GHD-related anemia specifically (class-level), not the general GHD population; no somatrogon-specific subgroup data located.

Regulatory status

"Anemia" is listed in the NGENLA label's Table 1 (Adverse Reactions Reported in ≥5% of Patients), at 10 patients (9.2%) of 109 on somatrogon versus 10 patients (8.7%) of 115 on daily somatropin over the 12-month pivotal trial. Not a labeled warning or monitoring requirement beyond the standard adverse-reaction table.

Population evidence

NGENLA US PI, Section 6.1, and independently confirmed via DailyMed's structured product labeling (same 9.2%/8.7% figures). The pivotal trial's own published safety narrative (Deal et al. 2022, PMID 35405011) separately reports anemia as a treatment-related adverse event in 7 patients (6.4%) on somatrogon and 7 patients (6.1%) on daily somatropin, a narrower "treatment-related causality" subset of the label's broader all-causality 9.2%/8.7% figures; both cuts of the same trial show closely matched rates between arms. PubMed title/abstract search for "somatrogon"[tiab] AND ("hemoglobin"[tiab] OR "hematocrit"[tiab] OR "oxygen"[tiab]) returned zero results, confirming no peer-reviewed paper's title or abstract specifically addresses hemoglobin, hematocrit, or oxygen delivery for this drug beyond the adverse-reaction table entry itself. Class-level: Miniero, Altomare, Rubino et al. (2012), J Pediatr Hematol Oncol, PMID 22584781, on rhGH (daily somatropin) treatment of children with idiopathic GHD-related anemia; the individual abstract page could not be retrieved in this review (see access notes), so exact sample size and effect magnitude are not confirmed and are not asserted, consistent with the prior companion dossiers' treatment of this same source.

Mechanism

Named, class-level: GH/IGF-1 stimulates erythropoiesis directly and via erythropoietin; GHD is an established, often mild and subclinical, cause of normocytic anemia generally reported to improve with any effective GH replacement. The drug-specific label data neither confirms nor contradicts this mechanism for somatrogon, since the anemia rate is essentially equal between the somatrogon and active-comparator arms.

Counter-evidence held on record

The label's own non-differential anemia rate is the strongest counter-evidence against a somatrogon-specific oxygen-delivery deficit found in this review, and is presented as such rather than omitted because it happens to be a null result. This is graded yellow, not orange, because the drug-specific data shows no attributable deficit (a near-equal rate versus active comparator), not a real bounded excess or deficiency; the class-level mechanism runs in the reverse (potentially corrective) direction. Not a basis for iron or B12 supplementation in the absence of a measured deficit.

  • Deal CL, Steelman J, Vlachopapadopoulou E, et al. Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study. — Pivotal registration RCT (NCT02968004), n=224 (109 somatrogon, 115 daily somatropin), prepubertal children, 12 months. Used for IGF-1 SDS, glucose/HbA1c/insulin, anemia adverse-event rate, and bone-age data. PubMed's individual abstract page was inaccessible via direct fetch (bot-verification) on the first attempt during this review; the Oxford Academic full-text page was used successfully instead.PubMed direct abstract page (pubmed.ncbi.nlm.nih.gov/35405011) returned a bot-verification/reCAPTCHA page on the first fetch attempt in this review; the Oxford Academic article page (academic.oup.com/jcem/article/107/7/e2717/6566444) was used successfully as the source of record instead.
  • Miniero R, Altomare F, Rubino M, et al. Effect of Recombinant Human Growth Hormone (rhGH) on Hemoglobin Concentration in Children With Idiopathic Growth Hormone Deficiency-related Anemia. — Title and journal citation confirmed via PubMed listing in the companion B002/B005 dossiers; individual abstract page returned a bot-verification page on repeated attempts across this and the prior reviews. Exact sample size and effect magnitude not confirmed and not asserted.PubMed abstract page inaccessible (bot-verification) in this and the companion dossiers' reviews.

ATP production, class-level, null in the one direct study

Yellow — Low

See study details

No somatrogon-specific ATP study exists; the one study that directly measured skeletal-muscle ATP resynthesis kinetics in adults treated with daily somatropin found no significant difference from untreated GHD patients or healthy controls.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: This entire entry is the null finding, for daily-dosed somatropin; not separately tested for somatrogon's weekly, structurally distinct exposure profile.
  • At-risk subgroups: None identified.

Regulatory status

Not addressed in the NGENLA label.

Population evidence

No study of somatrogon and ATP production was found. PubMed title/abstract search for "somatrogon"[tiab] AND "ATP"[tiab] returned zero results, confirmed directly. Class-level: Sinha et al. (2013/2014), PMID 23711232, the same study and cohort as the Mitochondrial burden entry (see Overlap map). Phosphocreatine (PCr) recovery half-time, a direct kinetic marker of mitochondrial ATP resynthesis capacity, did not differ significantly between 23 daily-somatropin-treated GHD adults, 22 untreated GHD adults, and 20 healthy controls.

Mechanism

None established; this entry documents an explicitly tested and negative finding in a population treated with daily somatropin via the same GH-receptor pathway somatrogon also activates, though through a structurally distinct circulating molecule.

Counter-evidence held on record

No study found in the opposite direction for any GH product. Presented as reassuring class-level context from a single cross-sectional study of daily dosing, not a guarantee for somatrogon specifically, and not a replacement for individualized clinical monitoring of fatigue in treated patients.

  • Sinha A, Hollingsworth KG, Ball S, Cheetham T. Impaired quality of life in growth hormone-deficient adults is independent of the altered skeletal muscle oxidative metabolism found in conditions with peripheral fatigue. — Cross-sectional study, n=65 (22 untreated GHD, 23 daily-somatropin-treated GHD, 20 controls); 31P-MRS phosphocreatine recovery kinetics; no significant difference across groups. Verified in this project's companion B002 and B005 dossiers; not independently re-fetched in this specific review given the Europe PMC/Semantic Scholar/OpenAlex access constraints described below. Used class-level for the Mitochondrial burden and ATP production entries.Not independently re-fetched in this review; relied on prior verification from the companion B002/B005 dossiers, disclosed explicitly.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • General "growth hormone/HGH depletes vitamins and minerals" framing, applied to Ngenla specifically

    Where it comes from: Not attributable to any specific source found. Checked GoodRx, Medscape, and a targeted search for "somatrogon Ngenla depletes nutrients vitamin mineral deficiency."

    Why it fails: No consumer source, practitioner content, or retailer page located during this review made a specific "somatrogon/Ngenla depletes X" claim, unlike commonly circulated narratives for metformin (B12), statins (CoQ10), or proton-pump inhibitors (B12/magnesium). The real, drug-specific mineral and metabolic effects found (phosphate/ALP/PTH elevation, fluid retention, decreased insulin sensitivity, IGF-1 threshold excursions) all run toward excess or altered handling, not depletion, and are graded above rather than left as an unsupported claim.

All references used above
  1. NGENLA (somatrogon-ghla) injection, for subcutaneous use, US Prescribing Information. — FDA-approved labeling: clinical pharmacology (12.1-12.3), warnings and precautions (5.1-5.14), adverse reactions (6.1), drug interactions (7), use in specific populations (8). Fetched and read directly; re-queried a second time specifically for Section 6.1 table detail and the eosinophil shift percentage.
  2. DailyMed. NGENLA- somatrogon-ghla injection, solution. — Used to independently re-confirm Sections 5.14, 6.1, 12.1-12.3, and the exact anemia adverse-reaction percentages (9.2% vs. 8.7%).
  3. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index, H01AC08 somatrogon. — Confirms ATC classification.
  4. Deal CL, Steelman J, Vlachopapadopoulou E, et al. Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study. — Pivotal registration RCT (NCT02968004), n=224 (109 somatrogon, 115 daily somatropin), prepubertal children, 12 months. Used for IGF-1 SDS, glucose/HbA1c/insulin, anemia adverse-event rate, and bone-age data. PubMed's individual abstract page was inaccessible via direct fetch (bot-verification) on the first attempt during this review; the Oxford Academic full-text page was used successfully instead.PubMed direct abstract page (pubmed.ncbi.nlm.nih.gov/35405011) returned a bot-verification/reCAPTCHA page on the first fetch attempt in this review; the Oxford Academic article page (academic.oup.com/jcem/article/107/7/e2717/6566444) was used successfully as the source of record instead.
  5. Stawerska R, et al. Extension of the Phase 3 Trial of Somatrogon in Children with Growth Hormone Deficiency: 3 Years of Safety and Efficacy. — Open-label 3-year extension of the pivotal trial, n=212 (OLE Year 1), n=177 (OLE Year 2). Used for long-term IGF-1 SDS, HbA1c stability, and adverse-event rate data.
  6. Tamaro G, Rodaro C, Fachin A, Fabretto A, Tornese G. Two-year real-world experience with somatrogon in children and adolescents with growth hormone deficiency. — Real-world cohort, n=40, March 2023-January 2025. Used for the IGF-1 threshold-excursion subgroup finding (13% exceeding +2 SDS in the early phase) and adverse-event data.
  7. Canadian Agency for Drugs and Technologies in Health (CADTH). Clinical Review, Somatrogon (Ngenla). — Health technology assessment clinical review summarizing the pivotal and crossover trials (CP-4-006, CP-4-009, C0311002) and the IGF-1-based dose-reduction protocol (2 repeated day-4 IGF-I SDS >2.0 triggers a 15% dose reduction; normalization target -0.5 to 1.5 SDS). Many specific adverse-event percentages in the source document itself were redacted (shown as "||||%") as confidential commercial information; only the unredacted figures and protocol language quoted above were used.Several adverse-event percentages in this source are redacted in the publicly available document itself (marked "||||%"); not asserted or estimated here.
  8. European Medicines Agency. Ngenla (somatrogon), European public assessment report (EPAR) overview. — Used to cross-check mechanism-of-action description and adverse-effect summary; contains no lab-value or nutrient-specific data beyond what the FDA label already provides.
  9. DrugBank. Somatrogon, DB14960. — Used for molecular structure (fusion of hGH with the carboxy-terminal peptide of hCG beta-subunit, molecular weight ~30,465 Da aglycosylated) and mechanism detail (GH-receptor binding, JAK2 activation, STAT5b signaling). Full pharmacokinetic dataset behind a login wall; not asserted beyond what the free preview provided.
  10. Wikipedia. Somatrogon. — Used only to cross-check the fusion-protein structure description and approval-history dates (Australia November 2021, EU February 2022, US June 2023) against DrugBank and the FDA label.
  11. Medscape Reference. Ngenla (somatrogon) dosing, indications, interactions, adverse effects. — Clinician-facing reference used to independently cross-check the label's monitoring recommendations (glucose, thyroid, phosphate/ALP/PTH, cortisol, fundoscopic exam) and, separately, for the circulating-claim audit; no nutrient-depletion claims found.
  12. GoodRx. Ngenla (somatrogon): Uses, Side Effects, Dosage & Reviews. — Consumer reference used for the circulating-claim audit; no nutrient-depletion claims found.
  13. "Somatrogon: Hyperglycaemia." — Located via Crossref bibliographic search under the somatrogon drug name. On inspection, the accessible preview page's cited reference resolves to Ying Y-Q et al., Growth Hormone and IGF Research (2018), "Efficacy and safety of recombinant human growth hormone in treating Chinese children with idiopathic short stature," a generic-rhGH, non-GHD, non-somatrogon study. Full case text is paywalled, so it cannot be confirmed whether this item genuinely concerns somatrogon or is a database mislabeling; not relied on for any graded claim.Full text paywalled; the one reference visible on the preview page does not concern somatrogon. Treated as unverifiable and excluded from grading, disclosed rather than silently dropped.
  14. "Somatrogon: Increased fasting sugar." — Located via Crossref bibliographic search under the somatrogon drug name. On inspection, the accessible preview page's cited reference resolves to an unrelated anaesthesia case report ("Anaesthetic challenges of Ellis-van Creveld syndrome," Kaur et al., J Clin Anesth, 2018). Full case text is paywalled; not relied on for any graded claim.Full text paywalled; the one reference visible on the preview page does not concern somatrogon. Treated as unverifiable and excluded from grading, disclosed rather than silently dropped.
  15. "Somatrogon: Diabetic ketoacidosis." — Located via Crossref bibliographic search under the somatrogon drug name. On inspection, the accessible preview page's cited reference resolves to Gonç EN et al., JCRPE (2017), a case of PCSK1 deficiency with transient diabetes during growth hormone therapy, unrelated to somatrogon (which had not yet completed Phase 3 trials at this date). Full case text is paywalled; not relied on for any graded claim.Full text paywalled; the one reference visible on the preview page does not concern somatrogon. Treated as unverifiable and excluded from grading, disclosed rather than silently dropped.
  16. Sinha A, Hollingsworth KG, Ball S, Cheetham T. Impaired quality of life in growth hormone-deficient adults is independent of the altered skeletal muscle oxidative metabolism found in conditions with peripheral fatigue. — Cross-sectional study, n=65 (22 untreated GHD, 23 daily-somatropin-treated GHD, 20 controls); 31P-MRS phosphocreatine recovery kinetics; no significant difference across groups. Verified in this project's companion B002 and B005 dossiers; not independently re-fetched in this specific review given the Europe PMC/Semantic Scholar/OpenAlex access constraints described below. Used class-level for the Mitochondrial burden and ATP production entries.Not independently re-fetched in this review; relied on prior verification from the companion B002/B005 dossiers, disclosed explicitly.
  17. Kościuszko M et al. Cardiovascular Effects of Growth Hormone: Preliminary Study on Oxidative Stress in Adults with Growth Hormone Deficiency. — Prospective observational study, n=15 adult-onset GHD adults on daily somatropin (Omnitrope), 12-month follow-up. Verified in this project's companion B002 and B005 dossiers; not independently re-fetched in this review.Preprint, not yet peer-reviewed; graded as Tier B/C for the class, never Tier A or B for somatrogon specifically since the drug is not in this cohort. Not independently re-fetched in this review.
  18. Yu Z, Wang Y, Zhang F, et al. Deletion of hepatic growth hormone receptor (GHR) alters the mouse gut microbiota by affecting bile acid metabolism. — Mouse hepatic GHR-knockout model (loss of GH signaling), not exogenous GH administration. Verified in this project's companion B002 and B005 dossiers; not independently re-fetched in this review.Not independently re-fetched in this review; relied on prior verification from the companion B002/B005 dossiers, disclosed explicitly.
  19. Miniero R, Altomare F, Rubino M, et al. Effect of Recombinant Human Growth Hormone (rhGH) on Hemoglobin Concentration in Children With Idiopathic Growth Hormone Deficiency-related Anemia. — Title and journal citation confirmed via PubMed listing in the companion B002/B005 dossiers; individual abstract page returned a bot-verification page on repeated attempts across this and the prior reviews. Exact sample size and effect magnitude not confirmed and not asserted.PubMed abstract page inaccessible (bot-verification) in this and the companion dossiers' reviews.
  20. Vihervuori E, Cook JD, Siimes MA. Iron status of children with short stature during accelerated growth due to growth hormone treatment. — n=35 children with short stature, 6 months of daily GH treatment. Ferritin decreased, transferrin increased, soluble transferrin receptor minimally changed. Verified in this project's companion B002/B005 dossiers; not independently re-fetched in this review. Used class-level for the Iron entry.Not independently re-fetched in this review.
  21. Vihervuori E, et al. Hemoglobin level is linked to growth-hormone-dependent proteins in short children. — n=40 short children, 12 months daily rhGH. Hemoglobin rose 0.42 g/dL overall, correlating with IGF-1/IGFBP-3 but not erythropoietin. Verified in this project's companion B002/B005 dossiers; not independently re-fetched in this review. Used class-level for the Iron entry's mechanism.Not independently re-fetched in this review.
  22. Brandão-Neto J, Kimachi T, Veríssimo JM, Shuhama T, Marchini JS, Antunes-Rodrigues J. Acute effects of human growth hormone on zinc, copper, calcium and magnesium metabolism in normal subjects. — Acute IV-infusion study, n=7 healthy adults, single 60-minute infusion of pituitary-derived hGH. Verified in this project's companion B002/B005 dossiers; not independently re-fetched in this review. Used class-level for the Copper entry.Single IV bolus dosing, not chronic subcutaneous dosing; opposite-direction results at two doses tested limit generalization. Not independently re-fetched in this review.
  23. Aihara K, Nishi Y, Hatano S, et al. Zinc, copper, manganese, and selenium metabolism in patients with human growth hormone deficiency or acromegaly. — Pituitary-derived hGH era cohort. Verified in this project's companion B002/B005 dossiers; not independently re-fetched in this review. Used class-level for the Copper entry.Not independently re-fetched in this review.
  24. Pankratova MS et al. Imbalance in the blood antioxidant system in growth hormone-deficient children before and after 1 year of recombinant growth hormone therapy. — n=11 treatment-naive GHD children, 12 months of daily recombinant GH; ceruloplasmin unchanged. Verified in this project's companion B002/B005 dossiers; not independently re-fetched in this review.Not independently re-fetched in this review.
  25. Wei S, Tanaka H, Kubo T, Ono T, Kanzaki S, Seino Y. Growth hormone increases serum 1,25-dihydroxyvitamin D levels and decreases 24,25-dihydroxyvitamin D levels in children with growth hormone deficiency. — n=12 GHD children, 6 months daily GH. Verified in this project's companion B002/B005 dossiers; not independently re-fetched in this review. Used class-level for the Vitamin D entry.Not independently re-fetched in this review.
  26. Durá-Travé T, Gallinas-Victoriano F, Moreno-González P, et al. Vitamin D status and response to growth hormone treatment in prepubertal children with growth hormone deficiency. — n=98 GHD children vs. 247 controls, 24 months daily GH; no change in vitamin D levels. Verified in this project's companion B002/B005 dossiers; not independently re-fetched in this review. Used class-level for the Vitamin D entry.Not independently re-fetched in this review.
  27. Durá-Travé T, Gallinas-Victoriano F. Vitamin D and Parathyroid Hormone during Growth Hormone Treatment. — n=110 GHD children vs. 377 controls, 48 months. Calcidiol unchanged (P=0.501); PTH rose independent of vitamin D status. Verified in this project's companion B002/B005 dossiers; not independently re-fetched in this review. Used class-level for the Vitamin D entry and the Overlap map.Not independently re-fetched in this review.
  28. Hamza RT, Hamed AI, Sallam MT. Vitamin D Status in Prepubertal Children with Isolated Idiopathic Growth Hormone Deficiency: Effect of Growth Hormone Therapy. — n=50 GHD children vs. 50 controls; 25(OH)D rose after 1 year of daily GH therapy. Verified in this project's companion B002/B005 dossiers; not independently re-fetched in this review. Used class-level as a reverse-direction finding, in tension with the larger null studies above.Not independently re-fetched in this review.
  29. Lamb YN. Somatrogon: First Approval. — Narrative drug-profile review; title, journal, and DOI confirmed via Crossref bibliographic search. Used for background context on approval history; not cited for any graded claim.
  30. Various authors. Somatrogon injection for the treatment of pediatric growth hormone deficiency with comparison to other LAGH products. — Comparative review of long-acting GH products. Located via search; the PubMed abstract page returned a rate-limited (HTTP 429) response on the one attempt made in this review and was not successfully fetched. Not cited for any graded claim; disclosed as an access limitation rather than omitted.HTTP 429 rate-limit on the single fetch attempt made in this review; not opened, not cited for any claim.